Literature DB >> 16015694

Evaluation of serum cathepsin B and D in relation to clinicopathological staging of colorectal cancer.

Elzbieta Skrzydlewska1, Mariola Sulkowska, Andrzej Wincewicz, Mariusz Koda, Stanislaw Sulkowski.   

Abstract

AIM: Proteolytic degradation of the extracellular matrix facilitates cancer invasion and promotes metastasis. The study aims at evaluation of preoperative and postoperative serum cathepsins B and D levels in correlation with selected anatomoclinical features of colorectal cancer.
METHODS: Blood samples were collected from 63 colorectal cancer patients before curative operation of the tumor 10 d later. Blood that was obtained from 20 healthy volunteers, served as a control. The activity of cathepsin B was measured with Bz-DL-arginine-pNA as a substrate at pH 6.0, while cathepsin D activity was determined with urea-denatured hemoglobin (pH 4.0).
RESULTS: The preoperative and postoperative activities of cathepsin B were significantly (P<0.00001) lower in serum of colorectal cancer patients than in control group. However, postoperative values of this protease were significantly increased in comparison with preoperative ones (P = 0.031). Activity of cathepsin D appeared to be significantly higher in colorectal cancer sera (P<0.00001) compared with controls. No statistically significant differences between preoperative and postoperative activity of cathepsin D were noted (P = 0.09). We revealed a strong linkage of cathepsins' levels with lymph node status and pT stage of colorectal cancer.
CONCLUSION: Blood serum activities of cathepsin B and D depend on the time of sampling, tumor size and lymph node involvement. Significantly, increased activity of cathepsin D could indicate a malignant condition of the large intestine. In our work, the serum postoperative decrease of cathepsin B activity appears as an obvious concomitant of local lymph node metastasis-the well-known clinicopathological feature of poor prognosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16015694      PMCID: PMC4615447          DOI: 10.3748/wjg.v11.i27.4225

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  32 in total

1.  Trypsin is produced by and activates protease-activated receptor-2 in human cancer colon cells: evidence for new autocrine loop.

Authors:  Robert Ducroc; Claire Bontemps; Katia Marazova; Hélène Devaud; Dalila Darmoul; Marc Laburthe
Journal:  Life Sci       Date:  2002-02-08       Impact factor: 5.037

2.  Increased cathepsin D level in the serum of patients with metastatic breast carcinoma detected with a specific pro-cathepsin D immunoassay.

Authors:  J P Brouillet; F Dufour; G Lemamy; M Garcia; N Schlup; J Grenier; J C Mani; H Rochefort
Journal:  Cancer       Date:  1997-06-01       Impact factor: 6.860

3.  Human trypsinogen in colorectal cancer.

Authors:  S J Williams; D C Gotley; T M Antalis
Journal:  Int J Cancer       Date:  2001-07-01       Impact factor: 7.396

4.  Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumour tissues.

Authors:  M R Buck; D G Karustis; N A Day; K V Honn; B F Sloane
Journal:  Biochem J       Date:  1992-02-15       Impact factor: 3.857

5.  Prognostic significance of matrix metalloproteinase-2, cathepsin D, and tenascin-C expression in colorectal carcinoma.

Authors:  Banu Sis; Ozgul Sağol; Ali Küpelioğlu; Selman Sokmen; Cem Terzi; Mehmet Fuzun; Erdener Ozer; Paul Bishop
Journal:  Pathol Res Pract       Date:  2004       Impact factor: 3.250

6.  MCF7 mammary cancer cells respond to bFGF and internalize it following its release from extracellular matrix: a permissive role of cathepsin D.

Authors:  P Briozzo; J Badet; F Capony; I Pieri; P Montcourrier; D Barritault; H Rochefort
Journal:  Exp Cell Res       Date:  1991-06       Impact factor: 3.905

7.  Cathepsin B expression in colorectal carcinomas correlates with tumor progression and shortened patient survival.

Authors:  E Campo; J Muñoz; R Miquel; A Palacín; A Cardesa; B F Sloane; M R Emmert-Buck
Journal:  Am J Pathol       Date:  1994-08       Impact factor: 4.307

8.  Cathepsin B and cathepsin D expression in the progression of colorectal adenoma to carcinoma.

Authors:  Maroulio Talieri; Sofia Papadopoulou; Andreas Scorilas; Dimitrios Xynopoulos; Niki Arnogianaki; George Plataniotis; Julia Yotis; Niki Agnanti
Journal:  Cancer Lett       Date:  2004-03-08       Impact factor: 8.679

9.  Immunohistochemical localization of cathepsins D and E in human gastric cancer: a possible correlation with local invasive and metastatic activities of carcinoma cells.

Authors:  K Matsuo; I Kobayashi; T Tsukuba; T Kiyoshima; Y Ishibashi; A Miyoshi; K Yamamoto; H Sakai
Journal:  Hum Pathol       Date:  1996-02       Impact factor: 3.466

10.  Cathepsin B acts as a dominant execution protease in tumor cell apoptosis induced by tumor necrosis factor.

Authors:  L Foghsgaard; D Wissing; D Mauch; U Lademann; L Bastholm; M Boes; F Elling; M Leist; M Jäättelä
Journal:  J Cell Biol       Date:  2001-05-28       Impact factor: 10.539

View more
  6 in total

1.  Vasculopathy in type 2 diabetes mellitus: role of specific angiogenic modulators.

Authors:  Enas A Hamed; Madeha M Zakary; Reffat M Abdelal; Effat M Abdel Moneim
Journal:  J Physiol Biochem       Date:  2011-02-19       Impact factor: 4.158

2.  Candidate serological biomarkers for cancer identified from the secretomes of 23 cancer cell lines and the human protein atlas.

Authors:  Chih-Ching Wu; Chia-Wei Hsu; Chi-De Chen; Chia-Jung Yu; Kai-Ping Chang; Dar-In Tai; Hao-Ping Liu; Wen-Hui Su; Yu-Sun Chang; Jau-Song Yu
Journal:  Mol Cell Proteomics       Date:  2010-02-01       Impact factor: 5.911

3.  Interaction of the hepatitis B spliced protein with cathepsin B promotes hepatoma cell migration and invasion.

Authors:  Wan-Nan Chen; Jin-Yan Chen; Bo-Yan Jiao; Wan-Song Lin; Yun-Li Wu; Ling-Ling Liu; Xu Lin
Journal:  J Virol       Date:  2012-10-03       Impact factor: 5.103

4.  Reevaluating cathepsin D as a biomarker for breast cancer: serum activity levels versus histopathology.

Authors:  Daniel E Abbott; Naira V Margaryan; Jacqueline S Jeruss; Seema Khan; Virginia Kaklamani; David J Winchester; Nora Hansen; Alfred Rademaker; Zhila Khalkhali-Ellis; Mary J C Hendrix
Journal:  Cancer Biol Ther       Date:  2010-01-15       Impact factor: 4.742

Review 5.  Role of lysosomes in physiological activities, diseases, and therapy.

Authors:  Ziqi Zhang; Pengfei Yue; Tianqi Lu; Yang Wang; Yuquan Wei; Xiawei Wei
Journal:  J Hematol Oncol       Date:  2021-05-14       Impact factor: 17.388

6.  The feasibility of enzyme targeted activation for amino acid/dipeptide monoester prodrugs of floxuridine; cathepsin D as a potential targeted enzyme.

Authors:  Yasuhiro Tsume; Gordon L Amidon
Journal:  Molecules       Date:  2012-03-26       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.